AI assistant
ABBOTT LABORATORIES — Delisting Announcement 2007
Jan 10, 2007
29777_dlst_2007-01-10_e73af3ec-0f85-48c1-9fcb-2d9ffa5f7077.zip
Delisting Announcement
Open in viewerOpens in your device viewer
25 1 a07-1548_125.htm VOLUNTARY WITHDRAWAL OF SECURITIES FROM LISTING AND REGISTRATION
| UNITED STATES | |
|---|---|
| SECURITIES | |
| AND EXCHANGE COMMISSION | |
| Washington, | |
| D.C. 20549 | |
| FORM 25 | |
| NOTIFICATION | |
| OF REMOVAL FROM LISTING AND/OR | |
| REGISTRATION | |
| UNDER SECTION 12(b) OF THE | |
| SECURITIES | |
| EXCHANGE ACT OF 1934. | |
| Commission File Number | 001-2189 |
| Abbott Laboratories and NYSE Arca, Inc. (f/k/a The | |
| Pacific Exchange, Inc.) | |
| (Exact | |
| name of Issuer as specified in its charter, and name of Exchange where | |
| security is listed and/or registered) | |
| 100 Abbott Park Road, Abbott Park, Illinois | |
| 60064-6400, (847) 937-6100 | |
| (Address, | |
| including zip code, and telephone number, including area code, of Issuers | |
| principal executive offices) | |
| Common Shares, without par value | |
| (Description | |
| of class of securities) |
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17CFR240.12d2-2(a)(1)
o 17CFR240.12d2-2(a)(2)
o 17CFR240.12d2-2(a)(3)
o 17CFR240.12d2-2(a)(4)
o Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.(1)
x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements of the Securities Exchange Act of 1934, Abbott Laboratories (Name of Issuer or Exchange) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
| January 10, 2007 | By | Executive Vice
President, Finance and Chief Financial Officer |
| --- | --- | --- |
| Date | Name | Title |
(1) Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
SEQ.=1,FOLIO='',FILE='C:\fc\10115548945_D10466_1603061\1548-1-ma.htm',USER='jmsproofassembler',CD='Jan 10 11:55 2007'